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still missing real ones. MLR is necessary, but, as in our
report, should be interpreted conservatively, alongside other
forms of reasoning.
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To the Editor: Liu et al. constructed a transgenic mouse
(TM) model overexpressing CYP4F2.1 They found enhanced
20-hydroxyeicosatetraenoic acid (HETE) production and
elevated blood pressure in TM and a positive correlation of
blood pressure with urinary 20-HETE levels, suggesting that
these findings are directly transferable to humans. We feel
that this passage is not so straightforward. 20-HETE has both
pro- and antihypertensive properties, depending on the site
of action: vasculature vs kidney tubuli, a finding that marks
the difference also in animal models, in which 20-HETE is
either prohypertensive (spontaneously hypertensive rats) or
antihypertensive (Dahl salt-sensitive rats). In humans,
CYP4F2 has maximal expression at the renal tubular level,
suggesting a major action of CYP4F2 as a natriuretic
substance. Other studies, in which 20-HETE was measured
using gas chromatography–mass spectrometry techniques,
showed a prevalently antihypertensive role of human 20-
HETE: Laffer2 found that the altered response of 20-HETE is
associated with salt-sensitive hypertension, and our group3
found decreased levels of urinary 20-HETE in patients with
hypertension compared with matched controls.
Moreover, V433M polymorphism, which was cited by the
authors in support of their hypothesis, decreases the activity
of the enzyme in vitro,4 suggesting that a prohypertensive
action can be hypothesized only if it acts at tubular level.
Indeed, this variant was associated with prevalence of hyper-
tension and incidence of stroke in a large population,5 even
though this was found only in males, suggesting a possible
role of testosterone in its regulation, as indicated also by Liu.
Therefore, extrapolation of the findings from the TM model
to humans should be done cautiously. Nevertheless, these
results encourage active research on the effect of eicosanoids
derived by CYP450 in hypertension.
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Our colleagues recently established a novel CYP4F2
transgenic (TG) mouse model that showed increased
20-hydroxyeicosatetraenoic acid (HETE) production and
elevated blood pressure.1 We are thankful to Dr Fava for
his interest and opinion.2 20-HETE, a vasoconstrictor and
a sodium-reabsorption inhibitor, has both prohypertensive
and antihypertensive properties. Reports on the role of
20-HETE in blood pressure regulation remained diverse
both in population association studies, with positive
correlation in some studies3,4 but not in others, and in
rodent models, with a prohypertensive effect in sponta-
neously hypertensive rats but antihypertensive action in
Dahl salt-sensitive rats. These discrepancies indeed
prompted us to construct a CYP4F2 TG model to evaluate
the overall effect of 20-HETE in vivo.
TG mice expressing CYP4F2 at renal tubules and other
extrarenal tissues developed hypertension on increased
20-HETE production, suggesting that a prohypertensive
role of 20-HETE was dominant. As for the antihypertensive
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action, studies on both salt-sensitive rats and human salt-
sensitive hypertension5 have indicated the natriuretic role
of 20-HETE was closely related to high salt intake. It is not
clear in vivo whether the expression site of CYP4F2 is the
only place where 20-HETE works, or whether 20-HETE
could diffuse into the local and systemic circulation as
well. Detailed mechanisms underlying the hypertension
pathogenesis in our TG model have not been illustrated
yet, which therefore urged us to study further. Recently, we
induced 20-HETE synthesis by androgen in TG mice
and confirmed the prohypertensive role of 20-HETE
(not published). We are now investigating the natriuresis
of 20-HETE by feeding TG mice a high-salt diet.
1. Liu X, Zhao Y, Wang L et al. Overexpression of cytochrome P450 4F2
in mice increases 20-hydroxyeicosatetraenoic acid production and
arterial blood pressure. Kidney Int 2009; 75: 1288–1296.
2. Fava C, Montagnana M, Melander O. Overexpression of cytochrome P450
4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and
arterial blood pressure. Kidney Int 2009; 76: 913.
3. Liu H, Zhao Y, Nie D et al. Association of a functional cytochrome P450
4F2 haplotype with urinary 20-HETE and hypertension. J Am Soc Nephrol
2008; 19: 714–721.
4. Ward NC, Tsai IJ, Barden A et al. A single nucleotide polymorphism in the
CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE
excretion and blood pressure. Hypertension 2008; 51: 1393–1398.
5. Laffer CL, Laniado-Schwartzman M, Wang MH et al. Differential
regulation of natriuresis by 20-hydroxyeicosatetraenoic acid in human
salt-sensitive versus salt-resistant hypertension. Circulation 2003; 107:
574–578.
Xiaoliang Liu1 and Yanyan Zhao1
1Department of Medical Genetics, China Medical University, Shenyang,
Liaoning, China
Correspondence: Yangan Zhao, Department of Medical Genetics,
China Medical University, No. 92 Bei Er Road, Shenyang 110001, China.
E-mail: yyzhao@mail.cmu.edu.cn
The data on transplantation in
Saudi Arabia are complex and
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To the Editor: We read with interest the report on global
activity in live-donor kidney donation.1 However, we must
highlight a possible misinterpretation of the data therein. The
country of Saudi Arabia is presented as having the highest
reported living kidney donor transplant rate, at 32 per
million population (p.m.p.). From the annual report of the
Saudi Centre for Organ Transplantation2 (SCOT), it is clear
that only 260 transplants were performed in the country
in 2007 using live-donor kidneys. The rate is therefore
10.1 p.m.p. The SCOT report identifies—with laudable
transparency—an additional 597 kidney transplantations
carried out abroad on Saudi citizens. Undoubtedly, the
majority of these cases constitute unethical transplant
tourism. The SCOT data reveal Saudi Arabia’s admirable
progress toward national self-sufficiency through its
increasing self-reliance in organ procurement. Since 2005,
the number of patients transplanted abroad has steadily
decreased and deceased-donor organ donations have in-
creased to unprecedented levels. The Saudi authorities are
clearly taking responsibility for meeting the transplantation
needs of citizens and residents in the country, thereby
minimizing the harmful effects of transplant tourism.
The pursuit of self-sufficiency in organs for transplan-
tation is the only way to progress toward global justice in
transplantation. Responding to national organ needs avoids
predatory behavior at the expense of underprivileged popu-
lations in other countries. Although increased rates of living
donation in many countries are a positive sign of public
support for transplantation, caution is required when inter-
preting such information.
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We appreciate the careful reading of our article by Dr Noel,
who raises a valid point regarding kidney transplant activity
in Saudi Arabia.1 The Saudi Centre for Organ Transplanta-
tion reports both living related and unrelated kidney
transplants, a division which is clearly presented in our
Supplementary Table S2 available online.2 In 2006, we
reported 200 kidney transplants performed from living
related donors in Saudi Arabia, whereas 646 kidney
transplants were attributed to living unrelated donors. As
Dr Noel justly points out, some of these unrelated living
kidney donor transplants might reflect unethical transplant
tourism activity. Saudi Arabian data should be interpreted
with this information in mind. Nevertheless, it was our
intent to quantify living kidney donor transplant activity
internationally; as such, these figures could not be ignored.
The fact remains that rates of living kidney donation have
been increasing worldwide. Our report represents the most
comprehensive international summary of living kidney
donor rates to date, and enables transplant professionals
worldwide to put their rates into a global context.
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